Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: VYVGART achieves standard-of-care status in 5+ indications simultaneously, driving margins toward 40%+.
FcRn Class Competition: Next-generation competitors outcompete on pricing or efficacy, eroding market share.
argenx is a premier hyper-growth biotech firm transitioning to a commercial powerhouse. Its lead asset, VYVGART, is rapidly becoming the standard of care in generalized Myasthenia Gravis (gMG) and is successfully expanding into CIDP. The 'pipeline-in-a-product' strategy provides a long-duration growth profile with multiple multi-billion dollar indication opportunities.
argenx is a premier hyper-growth biotech firm transitioning to a commercial powerhouse. Its lead asset, VYVGART, is rapidly becoming the standard of care in generalized Myasthenia Gravis (gMG) and is successfully expanding into CIDP. The 'pipeline-in-a-product' strategy provides a long-duration growth profile with multiple multi-billion dollar indication opportunities.
IP-protected antibody platform
Pipeline-in-a-product strategy
High demand for specialized autoimmune therapeutic platforms.
Strong Buy based on durable hyper-growth and multiple secondary indications.
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
In a sustained high-cost environment where CIDP expansion falters, valuation relies entirely on established gMG revenues.
IP-protected antibody platform
Pipeline-in-a-product strategy
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
The highlighted base cell is anchored to valuation synthesis sensitivity reference ($1,486.48). It is the reference value for this grid, not a separate standalone fair-value claim.
FCFF DCF remains positive at the base case: base FCFF $876.0M after capex $103.8M, with at 70.6% of . No cliff is projected unless capex/ or materially resets.
Transformation build phase.
High demand for specialized autoimmune therapeutic platforms.
Increased regulatory scrutiny and pricing pressure.
Transformation build phase.
Maintain full weight; volatility expected around readouts.
Reevaluate if structural thesis breaks or price exceeds $2700.
Strong Buy. Pipeline diversity reduces binary outcome risk.
High conviction in long-term pipeline-in-a-product strategy.
Strong Buy. Pipeline diversity reduces binary outcome risk.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Next-generation competitors erode pricing power, and secondary indications face regulatory delays.
Next-generation competitors outcompete on pricing or efficacy, eroding market share.
Regulatory delays or clinical failures across 3+ secondary indications cap revenue.
Failure to cross 15% operating margins by FY2027 due to sustained high SG&A.
The five developments that would weaken our investment case.
Failing to sustain operating profitability targets signals unconstrained commercialization expenses and clinical trial overhead, eroding operating leverage and undermining the core profitability profile required to justify current valuation multiples.
Current:25.4% for the period ended 2025-12-31
Alert if< 15.0% for any fiscal year through FY2027
Rejection of expanded therapeutic indications leaves the franchise overly dependent on existing neuromuscular revenues, drastically lowering long-term addressable market scale and restricting peak commercial sales potential.
Current:No secondary indication rejections filed as of 2026-05-20
Alert if>= 1 formal regulatory rejection or Complete Response Letter from the FDA or EMA across secondary indications within any 12-month period
Multiple late-stage clinical trial failures would invalidate the broad pipeline-in-a-product expansion narrative, stranding significant research capital and capping total addressable market expansion.
Current:Zero major pipeline trial failures as of 2026-05-20
Alert if> 3 clinical trial primary endpoint failures across secondary indications within any 24-month period
Sharp revenue growth deceleration indicates aggressive competitor entry in the core FcRn class and pricing pressure, eroding commercial dominance and compressing top-line expansion trajectory.
Current:89.6% for the period ended 2025-12-31
Alert if< 25.0% over any trailing twelve-month period
Significant compression in gross profitability signals intense pricing competition, mandatory rebates, or escalating manufacturing unit costs, reducing the gross cash flows needed to support commercial infrastructure.
Current:89.1% for the period ended 2025-12-31
Alert if< 80.0% over any trailing twelve-month period
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
VYVGART achieves standard-of-care status in 5+ indications simultaneously, driving margins toward 40%+.
Solid execution in gMG and CIDP with steady margin expansion towards the 30% target.
Warning level: < 15.0% for any fiscal year through FY2027. Failing to sustain operating profitability targets signals unconstrained commercialization expenses and clinical trial overhead, eroding operating leverage and undermining the core profitability profile required to justify current valuation multiples.
Warning level: >= 1 formal regulatory rejection or Complete Response Letter from the FDA or EMA across secondary indications within any 12-month period. Rejection of expanded therapeutic indications leaves the franchise overly dependent on existing neuromuscular revenues, drastically lowering long-term addressable market scale and restricting peak commercial sales potential.
Warning level: > 3 clinical trial primary endpoint failures across secondary indications within any 24-month period. Multiple late-stage clinical trial failures would invalidate the broad pipeline-in-a-product expansion narrative, stranding significant research capital and capping total addressable market expansion.
Warning level: < 25.0% over any trailing twelve-month period. Sharp revenue growth deceleration indicates aggressive competitor entry in the core FcRn class and pricing pressure, eroding commercial dominance and compressing top-line expansion trajectory.
Warning level: < 80.0% over any trailing twelve-month period. Significant compression in gross profitability signals intense pricing competition, mandatory rebates, or escalating manufacturing unit costs, reducing the gross cash flows needed to support commercial infrastructure.
| $1.23B |
| $2.19B |
| $4.15B |
| +116.2% |
| Gross profit | $381.3M | $1.11B | $1.96B | $3.70B | +113.3% |
| Operating income | $-727.1M | $-303.6M | $87.6M | $1.28B | — |
| Net income | $-709.6M | $-295.1M | $833.0M | $1.29B | — |
| EPS (diluted) | $-13.05 | $-5.16 | $12.78 | $19.57 | — |
| EBITDA | $-622.8M | $-192.3M | $105.2M | $1.31B | — |
| R&D | $663.4M | $859.5M | $983.4M | $1.36B | +27.2% |
| SG&A | $469.9M | $709.5M | $1.05B | $1.36B | +42.5% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 4,153,482,000 |
|---|---|
| Cost of revenue | 450,665,000 |
| Gross profit | 3,702,817,000 |
| Operating expenses | 2,648,202,000 |
| Operating income | 1,054,615,000 |
| Non-operating items and tax | 237,420,000 |
| Net income | 1,292,035,000 |
| Total assets | 8,682,698,000 |
|---|---|
| Cash | 3,491,289,000 |
| Current assets | 6,899,104,000 |
| Total liabilities | 1,359,606,000 |
| Current liabilities | 1,320,186,000 |
| Shareholders’ equity | 7,323,092,000 |
Point-in-time financial data used in the 2026-05-20 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | 410.7M | -622.8M | -709.6M | -862.8M | -966.6M | 103.8M | 104.3M | 157M | — | — | -4.2M | — | — | — | — | 800.7M | 12.4M | -176.2% | — | — | — |
| 2023-12-31 | 1.2B | -192.3M | -295.1M | -420.3M | -464.1M | 43.8M | 111.3M | 233M | — | — | -3.8M | — | — | — | — | 2B | 20M | -34.3% | — | — | — |
| 2024-12-31 | 2.2B | 105.2M | 833M | -82.7M | -151M | 68.3M | 17.5M | 235.2M | — | — | -7.6M | — | — | — | — | 1.5B | 39.1M | -0.8% | — | — | — |
| 2025-12-31 | 4.2B | 1.3B | 1.3B | 685.2M | 573.5M | 111.7M | 28.1M | 248.1M | — | — | -4.1M | — | — | — | — | 3.5B | 47.2M | 25.4% | — | — | — |
ARGX trades at 21.8x forward earnings against a peer median of 15.9x; EV/EBITDA of 34.2x against a peer median of 17.2x; 6 peers.
| Level | Action |
|---|---|
| Thesis break | Reevaluate if structural thesis breaks or price exceeds $2700. |
| Regeneron Pharmaceuticals Inc. |
| 11.7x |
| 4.4x |
| 13.3x |
| 14.5% |
| 20.7% |
| ALNY | Alnylam Pharmaceuticals, Inc. | 21.0x | 9.1x | 48.3x | 90.4% | 23.0% |
| INCY | Incyte Corporation | 10.6x | 3.6x | 9.8x | 30.8% | 25.6% |
| MRNA | Moderna Inc. | -11.0x | 8.2x | -6.2x | -36.6% | -131.1% |
